Investigation of Sars-Cov Antibody Levels After Covid-19 Vaccine in Chronic Hepatitis B Patients

dc.authorid Dursun, Ali Dogan/0000-0001-9056-0025
dc.authorscopusid 11941010000
dc.authorscopusid 59132809500
dc.authorscopusid 57196954194
dc.authorscopusid 8632573400
dc.authorscopusid 57221732903
dc.authorscopusid 7004038581
dc.authorscopusid 11939483500
dc.authorwosid Dursun, Ali Dogan/AAH-7617-2019
dc.contributor.author Kinikli, Sami
dc.contributor.author Afsar, Fatma Elcin
dc.contributor.author Dursun, Ali Dogan
dc.contributor.author Aksoy, Altan
dc.contributor.author Karahan, Gizem
dc.contributor.author Cesur, Salih
dc.contributor.author Urtimur, Ufuk
dc.contributor.other Basic Sciences
dc.date.accessioned 2024-07-05T15:23:58Z
dc.date.available 2024-07-05T15:23:58Z
dc.date.issued 2024
dc.department Atılım University en_US
dc.department-temp [Kinikli, Sami; Cesur, Salih; Hatipoglu, cigdem Ataman; Ertem, Gunay Tuncer; Erdinc, Fatma Sebnem; Urtimur, Ufuk] Hlth Sci Univ, Ankara Training & Res Hosp, Infect Dis & Clin Microbiol Clin, Ankara, Turkiye; [Afsar, Fatma Elcin] Baskent Univ, Fac Med, Dept Physiol, Konya, Turkiye; [Dursun, Ali Dogan] Atilim Univ, Vocat Sch Hlth Serv, Dept Med Serv & Tech, Ankara, Turkiye; [Aksoy, Altan] Univ Hlth Sci, Ankara Training & Res Hosp, Med Microbiol Dept, Ankara, Turkiye; [Karahan, Gizem] Minist Hlth Mamak State Hosp, Infect Dis Clin, Ankara, Turkiye en_US
dc.description Dursun, Ali Dogan/0000-0001-9056-0025 en_US
dc.description.abstract AIM: The aim was to compare SARS-CoV-2 IgG antibody levels in chronic hepatitis B patients and healthcare personnel selected as the control group and to determine factors such as age, gender, vaccine type, and number of vaccines that may affect the antibody levels. MATERIALS AND METHODS: 87 chronic hepatitis B (CHB) patients followed in Ankara Training and Research Hospital Infectious Diseases Clinic and Mamak State Hospital Infectious Diseases outpatient clinic and 89 healthcare personnel selected as the control group were included in the study. SARS-CoV-2 IgG antibody levels in the serum samples of patients and healthcare personnel who received the COVID-19 vaccine were studied with the ELISA method in the Microbiology Laboratory of Ankara Training and Research Hospital, using a commercial ELISA kit (Abbott, USA) in line with the recommendations of the manufacturer. In the study, SARS-CoV-2 IgG levels were compared in CHB patients and healthcare personnel. In addition, the relationship between SARS-CoV-2 antibody level, gender, average age, natural history of the disease, number of vaccinations, vaccine type (Coronavac TM vaccine alone, BNT162b2 vaccine alone or Coronavac TM and BNT162b2 vaccine (heterologous vaccination)), treatment duration of CHB was investigated. Statistical analyses were made in the SPSS program. A value of p <= 0.05 was considered statistically significant. FINDINGS: A total of 167 people, including 87 CKD patients and 80 healthcare personnel as the control group, were included in the study. SARS-CoV-2 IgG antibody levels were detected above the cut-off level in the entire study group, regardless of the vaccine type. No difference was detected in SARS-CoV-2 IgG titers after COVID-19 vaccination between CHB patients and healthcare personnel. There was a statistically significant difference in SARS-CoV-2 IgG antibody levels among individuals participating in the study according to vaccine types. Compared to those who received Coronavac TM vaccine alone, the average SARS-CoV-2 IgG level was found to be statistically significantly higher in those who received BNT162b2 vaccine alone or heterologous vaccination with Coronavac TM + BNT162b2 vaccine. There was no difference between the groups in terms of age, gender, number of vaccinations, natural transmission of the disease, and duration of antiviral therapy in the CHD patient group. CONCLUSION: As a result, SARS-CoV-2 IgG antibody levels above the cut-off value were achieved with Coronavac TM and BNT162b2 vaccines in both CHD patients and healthy control groups. however, both CHD patients and healthcare personnel had higher antibody levels than those who received BNT162b2 alone or those who received heterologous vaccination had higher antibody levels than those with Coronavac TM alone. Therefore, if there are no contraindications, BNT162b2 vaccine may be preferred in CHB and health personnel (Tab. 2, Ref. 14) . en_US
dc.identifier.citationcount 0
dc.identifier.doi 10.4149/BLL_2024_57
dc.identifier.endpage 381 en_US
dc.identifier.issn 0006-9248
dc.identifier.issn 1336-0345
dc.identifier.issue 6 en_US
dc.identifier.pmid 38757595
dc.identifier.scopus 2-s2.0-85193520425
dc.identifier.startpage 376 en_US
dc.identifier.uri https://doi.org/10.4149/BLL_2024_57
dc.identifier.uri https://hdl.handle.net/20.500.14411/2356
dc.identifier.volume 125 en_US
dc.identifier.wos WOS:001235481100005
dc.identifier.wosquality Q4
dc.institutionauthor Dursun, Ali Doğan
dc.institutionauthor Afşar, Fatma Elçin
dc.language.iso en en_US
dc.publisher Aepress Sro en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.scopus.citedbyCount 0
dc.subject chronic hepatitis B en_US
dc.subject healthcare personnel en_US
dc.subject COVID-19 en_US
dc.subject vaccination en_US
dc.subject SARS-CoV-2 IgG en_US
dc.title Investigation of Sars-Cov Antibody Levels After Covid-19 Vaccine in Chronic Hepatitis B Patients en_US
dc.type Article en_US
dc.wos.citedbyCount 0
dspace.entity.type Publication
relation.isAuthorOfPublication f051787a-8f55-4f2e-947e-babc594e7639
relation.isAuthorOfPublication 0f8192b0-5c72-42da-ae80-67ba0cb81e22
relation.isAuthorOfPublication.latestForDiscovery f051787a-8f55-4f2e-947e-babc594e7639
relation.isOrgUnitOfPublication c6d3b3b7-f103-4779-9789-92b2e2420f2d
relation.isOrgUnitOfPublication.latestForDiscovery c6d3b3b7-f103-4779-9789-92b2e2420f2d

Files

Collections